Sign up
Pharma Capital

Collagen Solutions in “stronger position” after difficult year

The loss of four key customer contracts meant revenues slipped year-on-year, but CEO Jamal Rushdy thinks the changes it made in the wake of those issues leave the company in a better position
surgeons in a hospital
Collagen signed a major customer contract last month

Collagen Solutions PLC (LON:COS) boss Jamal Rushdy has told investors that the company is in a stronger position after what was a difficult year for the regenerative med-tech group.

The loss of contracts with four key customers – valued at over £800,000 a year – meant revenue slipped 6% to £3.83mln in the 12 months ended March 31 (2017: £4.09mln).

READ: Collagen appoints new chief business officer

Underlying losses (LBITDA) widened slightly as well to £1.58mln (2017: £1.26mln). Collagen closed the period with just over £5mln of cash in the bank (2017: £9.0mln).

In response to the challenges, the AIM-quoted firm set about restructuring its business to bolster cash, improve margins and solidify the trajectory to profitability. Collagen also strengthened its board and executive team to help boost its commercial expertise.

The company still managed to bring on board 16 new customers and signed 14 new customer agreements during the year, while last month it signed a “major” contract which will help the top line this time around.

‘Significant year of growth ahead’

“On the one hand, we experienced a difficult year in terms of our sales performance and the necessity to mitigate several unexpected challenges in our core business,” said CEO Rushdy.

“However, I am pleased that our global team, and highly supportive board, faced these challenges head-on and achieved several positive outcomes during the year.

“I am confident the operational improvements and new organisational appointments we have made has put the Company in a much stronger position.”

Chairman David Evans added: “We anticipate that we will have a significant year of growth and change, and it will be a transitional year in terms of new product development and revenue generation.”

View full COS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.